Dr. Richard E. Holevas, MD

Dr. Holevas practices at Orange Coast Urology in Newport Beach, California.

Dr. Holevas' NPI, 1295807436, was assigned on November 14, 2006. Dr. Holevas graduated from Loma Linda University School Of Medicine in 1988. Dr. Holevas holds California license G66489.

Dr. Holevas' primary practice is Orange Coast Urology, at 520 Superior Ave, Newport Beach, CA 92663. The practice phone is (949) 646-1131.

Dr. Holevas' primary practice is Orange Coast Urology in Newport Beach, California. Dr. Holevas is also affiliated with Hoag Hospital Newport Beach. The medical group on file is Orange Coast Urology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Holevas practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Holevas' primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Holevas is board certified in urology by the American Board of Urology. Dr. Holevas is licensed in California.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and prostate cancer among the conditions Dr. Holevas treats.

CMS data shows 3,868 Medicare services from Dr. Holevas across 19 procedure codes in 2024, for 779 Medicare patients. Medicare paid $276,177 for them. Every service was in an office.

CMS counts 779 Medicare patients who saw Dr. Holevas in 2024. The largest group is 75 to 84, with 375 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 1% are also on Medicaid. Their average risk score is 1.19, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Holevas' median patient age at 74, with 12% women.

In 2024, Dr. Holevas wrote 1,936 Medicare Part D claims for 454 patients. 97% of them were for generic drugs. CMS names the drug for 1,857 of them, across 20 drugs with 11 or more claims each, at $102,191 in total drug cost. In 2023, CMS named 1,825 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Holevas for performance year 2024, reported individually. Dr. Holevas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Holevas, published from 2009 to 2010. The most frequent topics are Brachytherapy, Prostatic Neoplasms and Radiotherapy Dosage. Dr. Holevas has published most often in Brachytherapy. Dr. Holevas' most frequent co-authors are Luis I. Kobashi, MD, Richard Randall Reed, MD and Richard Barry Wilder, MD.

CMS Open Payments shows 136 general payments to Dr. Holevas from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Urogen Pharma, Inc. paid the most, $579.

Dmand AI lists 3 awards for Dr. Holevas, most recently CMS Stage 1 EHR in 2013.

Dr. Holevas graduated from Loma Linda University School Of Medicine in 1988. Dr. Holevas is a member of ACS.

Dr. Holevas is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.